title: Immunophenotypic characteristics and clinical relevance of CD56+ and CD56- extranodal nasal-type natural killer/T-cell lymphoma.
abstract: This study aimed to determine whether the phenotypic characteristics of the two subtypes of CD56+ and CD56- lymphoma have relevance for their clinical behavior and prognosis. The immunophenotypes of all patients were confirmed using standard criteria for CD20, CD3ε, CD56, cytotoxic molecules (T-cell intracellular antigen-1 [TIA-1] and granzyme B), and Ki-67, and in situ hybridization for Epstein-Barr virus (EBV)-encoded RNA (EBER). CD56 was expressed in 90 of 118 (76.3%) patients. The majority (83.3%) of patients with nasal natural killer/T-cell lymphoma (NKTCL) presented with CD56+ lymphoma, whereas patients with NKTCL of the extranasal upper aerodigestive tract were more likely to have CD56- lymphoma (53.6%, p < 0.000). A lower percentage of expression of granzyme B and Ki-67 (>50%) was found in patients with CD56- lymphoma compared with those with CD56+ lymphoma (p <0.05). The clinical characteristics and prognosis were comparable between patients with CD56+ and CD56- lymphomas. The corresponding overall survival and progression-free survival rates were 74.1% and 56.7%, respectively, for patients with CD56+ lymphoma compared with 81.6% and 60.5% for those with CD56- lymphoma (p > 0.05). There was no clinical or prognostic significance in determining the two subtypes of CD56+ and CD56- NKTCL based on their immunophenotypic profiles, which has clinical implications for pathological diagnosis and insight into disease behavior.
authors.affiliation: Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China. yexiong@yahoo.com
authors.forename: Ye-Xiong
authors.initials: YX
authors.lastname: Li
authors.forename: Hua
authors.initials: H
authors.lastname: Wang
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Feng
authors.forename: Qing-Feng
authors.initials: QF
authors.lastname: Liu
authors.forename: Wei-Hu
authors.initials: WH
authors.lastname: Wang
authors.forename: Ning
authors.initials: N
authors.lastname: Lv
authors.forename: Jing
authors.initials: J
authors.lastname: Jin
authors.forename: Shu-Lian
authors.initials: SL
authors.lastname: Wang
authors.forename: Yue-Ping
authors.initials: YP
authors.lastname: Liu
authors.forename: Hui
authors.initials: H
authors.lastname: Fang
authors.forename: Yong-Wen
authors.initials: YW
authors.lastname: Song
authors.forename: Xin-Fan
authors.initials: XF
authors.lastname: Liu
authors.forename: Li-Qiang
authors.initials: LQ
authors.lastname: Zhou
authors.forename: Zhao-Yang
authors.initials: ZY
authors.lastname: Wang
authors.forename: Zi-Hao
authors.initials: ZH
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D019002:CD56 Antigen / Q000032:analysis / Q000378:metabolism*; D002648:Child; D015331:Cohort Studies; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis* / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D019002:CD56 Antigen